nasopharyngeal-carcinoma

Documents about nasopharyngeal-carcinoma

• SBRT for Oligo-metastatic Lesions After Systemic Treatment of Primary Metastatic Nasopharyngeal Carcinoma#668825ClinicalTrials.gov
• The current role of immunotherapy in treating nasopharyngeal carcinoma#676312Europe PMC
• KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial#833330ClinicalTrials.gov
• Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma#837516ClinicalTrials.gov
• Two Cycles Versus Three Cyclle of CCRT for Low Risk Locoregionally Advanced Nasopharyngeal Carcinoma#861097ClinicalTrials.gov
• Effect of Chemoradiotherapy on Nutritional Status in Advanced NPC Patients#874141ClinicalTrials.gov
• Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Recurrent Nasopharyngeal Carcinoma#887789ClinicalTrials.gov
• Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Randomized Control Clinical Trial#868264ClinicalTrials.gov
• Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II)#226250ClinicalTrials.gov
• TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC#353283ClinicalTrials.gov
• KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial#444744ClinicalTrials.gov
• CTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal Carcinoma#805753ClinicalTrials.gov
• A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839#811441ClinicalTrials.gov
• A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma#829518ClinicalTrials.gov
• TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical Trial#160366ClinicalTrials.gov
• The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma#366605ClinicalTrials.gov
• Iparomlimab and Tuvonralimab Injection for Untreated Locally Advanced Nasopharyngeal Carcinoma#871891ClinicalTrials.gov
• Methylation-specific PCR Test for Early Screening and Early Diagnosis of Nasopharyngeal Carcinoma#878725ClinicalTrials.gov
• Late Sequelae of Childhood and Adolescent Nasopharyngeal Carcinoma Survivors After Radiotherapy#883904ClinicalTrials.gov
• Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma#884122ClinicalTrials.gov
• Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal Carcinoma#970011ClinicalTrials.gov
• Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial#888583ClinicalTrials.gov
• Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)#906216ClinicalTrials.gov
• Dynamic Risk Prediction of Severe Myelosuppression in Nasopharyngeal Carcinoma#834698ClinicalTrials.gov
• Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy#856336ClinicalTrials.gov
• A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma#888765ClinicalTrials.gov
• Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial#904687ClinicalTrials.gov
• PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma#904816ClinicalTrials.gov
• Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma#992870ClinicalTrials.gov
• Epstein-Barr virus reprograms immune escape in nasopharyngeal carcinoma#253493Europe PMC
• EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal Carcinoma#885649ClinicalTrials.gov
• Combination of Capecitabine and Oxaliplatin in Metastatic Nasopharyngeal Carcinoma#810228ClinicalTrials.gov
• Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial#852668ClinicalTrials.gov
• Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma#803352ClinicalTrials.gov
• A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma#803730ClinicalTrials.gov
• GP Combined With Nimotuzumab and Sintilimab as Induction Therapy for Nasopharyngeal Carcinoma#827784ClinicalTrials.gov
• A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma#863377ClinicalTrials.gov
• The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT#869516ClinicalTrials.gov
• Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma#900802ClinicalTrials.gov
• NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation#991722ClinicalTrials.gov
• QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.#444869ClinicalTrials.gov
• Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma#825004ClinicalTrials.gov
• Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer#908787ClinicalTrials.gov
• GP-induced Chemotherapy Combined With IMRT and TPF-induced Chemotherapy Combined With IMRT in the Treatment of Distant Metastatic Nasopharyngeal Carcinoma#849868ClinicalTrials.gov
• Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma#860409ClinicalTrials.gov
• Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition#891719ClinicalTrials.gov
• BH4 in the Prevention and Treatment of Radiation-induced Skin Reactions for Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)#979333ClinicalTrials.gov
• MRG003 Combined With Immunotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial#279523ClinicalTrials.gov
• PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma#845577ClinicalTrials.gov
• Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma#894915ClinicalTrials.gov